ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
ConcertAI and NeoGenomics (NASDAQ: NEO) have announced a joint software-as-a-service solution called CTO-H for hematological malignancies research. The solution provides the largest reference dataset ever created for hematological malignancies, featuring data from over 370,000 patient lives with 7-11 years of surveillance and comprehensive biomarker information.
The collaboration aims to address challenges in clinical trial design and execution in hematology research. CTO-H will be deployed as a SaaS solution within ConcertAI's CARAai™ cloud, with NeoGenomics providing specialized biomarker testing interpretation services. The solution will be available for pre-release evaluation immediately, with general availability scheduled for January 17, 2025.
ConcertAI e NeoGenomics (NASDAQ: NEO) hanno annunciato una soluzione software-as-a-service congiunta chiamata CTO-H per la ricerca sulle neoplasie ematologiche. La soluzione fornisce il più grande dataset di riferimento mai creato per le neoplasie ematologiche, con dati provenienti da oltre 370.000 pazienti con un periodo di sorveglianza di 7-11 anni e informazioni complete sui biomarcatori.
La collaborazione mira a affrontare le sfide nella progettazione e nell'esecuzione di studi clinici nella ricerca ematologica. CTO-H sarà implementato come soluzione SaaS all'interno del cloud CARAai™ di ConcertAI, con NeoGenomics che fornirà servizi di interpretazione dei test sui biomarcatori specializzati. La soluzione sarà disponibile per la valutazione pre-rilascio immediatamente, con una disponibilità generale prevista per il 17 gennaio 2025.
ConcertAI y NeoGenomics (NASDAQ: NEO) han anunciado una solución conjunta de software como servicio llamada CTO-H para la investigación de neoplasias hematológicas. La solución proporciona el conjunto de datos de referencia más grande jamás creado para enfermedades hematológicas, con datos de más de 370,000 vidas de pacientes con 7-11 años de seguimiento y una información completa sobre biomarcadores.
La colaboración tiene como objetivo abordar los desafíos en el diseño y la ejecución de ensayos clínicos en la investigación hematológica. CTO-H se implementará como una solución SaaS dentro de la nube CARAai™ de ConcertAI, con NeoGenomics proporcionando servicios especializados de interpretación de pruebas de biomarcadores. La solución estará disponible para evaluación previa al lanzamiento de inmediato, con disponibilidad general programada para el 17 de enero de 2025.
ConcertAI와 NeoGenomics (NASDAQ: NEO)가 혈액종양 연구를 위한 공동 소프트웨어 서비스 솔루션인 CTO-H를 발표했습니다. 이 솔루션은 7-11년의 추적 관찰과 포괄적인 바이오마커 정보가 포함된 37만 명 이상의 환자 생명에 대한 데이터를 특징으로 하는 혈액종양을 위한 가장 큰 참조 데이터 세트를 제공합니다.
이번 협력은 혈액학 연구에서 임상 시험 설계 및 실행의 문제를 해결하는 것을 목표로 합니다. CTO-H는 ConcertAI의 CARAai™ 클라우드 내에서 SaaS 솔루션으로 제공되며, NeoGenomics는 전문화된 바이오마커 테스트 해석 서비스를 제공합니다. 이 솔루션은 즉시 사전 출시 평가 가능하며, 일반 출시 예정일은 2025년 1월 17일입니다.
ConcertAI et NeoGenomics (NASDAQ: NEO) ont annoncé une solution conjointe de logiciel en tant que service appelée CTO-H pour la recherche sur les malignités hématologiques. La solution fournit le plus grand ensemble de données de référence jamais créé pour les malignités hématologiques, contenant des données provenant de plus de 370 000 vies de patients avec 7 à 11 ans de surveillance et des informations complètes sur les biomarqueurs.
La collaboration vise à relever les défis dans la conception et l'exécution d'essais cliniques en recherche hématologique. CTO-H sera déployé en tant que solution SaaS au sein du cloud CARAai™ de ConcertAI, avec NeoGenomics fournissant des services spécialisés d'interprétation des tests de biomarqueurs. La solution sera immédiatement disponible pour une évaluation avant lancement, avec une disponibilité générale prévue pour le 17 janvier 2025.
ConcertAI und NeoGenomics (NASDAQ: NEO) haben eine gemeinsame Software-as-a-Service-Lösung namens CTO-H für die Forschung zu hämatologischen Malignomen angekündigt. Die Lösung bietet den größten je erstellten Referenzdatensatz für hämatologische Malignome, der Daten von über 370.000 Patientenleben mit 7-11 Jahren Überwachung und umfassenden Biomarkerinformationen enthält.
Die Zusammenarbeit zielt darauf ab, Herausforderungen beim Design und der Durchführung von klinischen Studien in der Hämatologieforschung zu bewältigen. CTO-H wird als SaaS-Lösung innerhalb der CARAai™-Cloud von ConcertAI implementiert, wobei NeoGenomics spezialisierte Interpretationsdienste für Biomarkertests bereitstellt. Die Lösung wird sofort zur Vorabprüfung verfügbar sein, die allgemeine Verfügbarkeit ist für den 17. Januar 2025 geplant.
- Creation of industry's largest hematological malignancies reference dataset with 370,000+ patient records
- Extensive data coverage with 7-11 years of patient journey surveillance
- Partnership combines NeoGenomics' 500+ clinical diagnostic tests with ConcertAI's cloud platform
- General availability delayed until January 2025
Insights
The collaboration between ConcertAI and NeoGenomics introduces a significant advancement in hematological research through their CTO-H platform. With a database covering 370,000 patient lives and 7-11 years of surveillance data, this represents the largest hematological malignancies dataset ever assembled. The platform's comprehensive biomarker depth and clinical attributes position it as a powerful tool for optimizing clinical trial design and research analytics.
The solution addresses critical challenges in hematological research, particularly in patient population definition and control group representation. By providing deep multi-modal analysis capabilities, CTO-H could significantly reduce trial design complexity and accelerate patient recruitment - historically major bottlenecks in hematological clinical research. The integration with NeoGenomics' extensive diagnostic testing capabilities (>500 tests) adds substantial clinical validity to the platform.
The Software-as-a-Service (SaaS) deployment model through ConcertAI's CARAai™ cloud platform represents a strategic technological approach. This cloud-based solution enables scalable access to complex biomarker and clinical data, while maintaining security and compliance requirements essential for healthcare data. The integration of AI capabilities with such an extensive dataset creates powerful opportunities for pattern recognition and predictive analytics in clinical research.
The platform's ability to combine routine tests with specialized genetic variants in a unified system demonstrates sophisticated data architecture. The January 2025 release timeline suggests a thorough development and testing phase, indicating a robust enterprise-grade solution.
The new CTO-H provides the largest, longest and deepest view of hematological diseases ever created — establishing a new standard for clinical research
Starting in 2023, NeoGenomics and ConcertAI reimagined research solutions that healthcare providers and biopharma would need to manage the growing number of new therapeutic entities targeting hematological malignancies. As a result, they designed a highly representative database of more than 370,000 patient lives with clinical attributes, 7 to 11 years of patient journey surveillance, and exquisite biomarker depth from routine tests to highly specialized and genetic variants. Both companies believe CTO-H to be the single largest reference dataset for hematological malignancies ever created.
Over the last five years, the treatment landscape for hematological malignancies has transformed with a broader range of highly effective treatment options being available for patients. At the same time, the clinical development pipeline of the industry has also grown. It is challenging to define the population for an early-phase clinical trial and even harder to ensure the control group is representative of the current treatment paradigm. Late-phase clinical trials face even greater complexity in achieving their accruals in the targeted time owing to the study design, studies competing for the same patient population, and intra-research site competition for the same patients.1
“Hematological research is innately complex, with high heterogeneity of standard of care treatments, a longer duration of treatment before a relapse, and increasingly multi-factor measure of response and residual disease,” said Jeff Elton, PhD, founding CEO of ConcertAI. “As the deepest multi-modal solution specifically for hematological malignancies, CTO-H represents a significant achievement in advanced clinical analysis, study design and optimization, and study execution planning.”
“NeoGenomics offers more than 500 clinical diagnostic tests, with a large portion of these being in hematology and for hematological malignancies,” said Lindsey Gasparini, Vice President of Informatics at NeoGenomics. “CTO-H was many months in the making, and we’re excited about the value it will bring to our biopharma research customers. This solution allows biopharma to reconsider how they design clinical trials by increasing precision and reducing time along the clinical development process, which will ultimately accelerate meaningful biomedical innovation to our clinical partners and their patients.”
Under the collaboration, ConcertAI will be deploying CTO-H as a SaaS solution within its CARAai™ cloud. NeoGenomics will provide services relating to the interpretation of specialized biomarkers and testing, and the ability to access specific clinical expertise in assurance of the highest confidence analyses, study designs, and interpretations. CTO-H is available as a pre-release solution for evaluation as of this announcement and general availability on Jan. 17, 2025.
About ConcertAI
ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in
1 Targeted Oncology (2024) 19:797–809, https://doi.org/10.1007/s11523-024-01081-w
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205002549/en/
Treble
McKenzie Covell
concertai@treblepr.com
Source: ConcertAI
FAQ
What is the CTO-H solution announced by NeoGenomics (NEO) and ConcertAI?
When will NeoGenomics' (NEO) CTO-H solution be generally available?
How many patient records does NeoGenomics' (NEO) CTO-H database contain?
